Eli Lilly's Reyvow wins FDA nod for migraine relief, but side effects could limit sales: analyst

Eli Lilly
Eli Lilly's migraine drug Reyvow, formerly known as lasmiditan, scored an FDA nod Friday. (Eli Lilly)

Eli Lilly is already working to grow market share for its migraine prevention med Emgality, but now the company has a new medicine to add to its suite. 

Reyvow, a first-in-class drug Lilly picked up with its 2017 CoLucid buyout, won approval Friday to treat migraines as they occur. Formerly known as lasmiditan, Reyvow will be the latest launch for the company's growing pain and migraine franchise.

Lilly Bio-Medicines President Patrik Jonsson said in a statement the nod is “an exciting development for patients and physicians seeking the potential for pain freedom when a migraine attack happens." The company's own Emgality, along with its CGRP brethren, is approved as a migraine-prevention agent, but not to treat acute migraine.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

The FDA approved Reyvow based on two trials in a total of more than 3,100 patients. In the studies, patients who took Reyvow were more likely to have their migraine symptoms resolved after two hours than those who took placebo. 

RELATED: Eli Lilly files for FDA approval of migraine drug lasmiditan

In a note to clients, SVB Leerink analyst Marc Goodman said the new drug has “solid efficacy” and should be a “welcome" addition for doctors and patients, but that its label and side effects will prevent it from being a “significant” drug revenue-wise. Instead, he believes it’ll be a niche medicine with under $500 million in peak sales. 

Reyvow’s side effects include dizziness and somnolence, and Goodman notes that the Drug Enforcement Agency will have to schedule the new med before it can launch. The label also says patients shouldn’t drive for at least 8 hours after taking the drug.  

Lilly shelled out $960 million for Reyvow's developer, CoLucid, in 2017 and filed the drug for approval last November. 

RELATED: Don't fret about Lilly's 3rd-to-market start in CGRP, executive says. It's got big plans in migraine and pain

Meanwhile, even though Emgality was the third CGRP drug to win FDA approval and trailed rivals to launch, it’s been growing market share quickly in recent months. It held 31% of the treatment category as of mid-August. The drug also picked up a cluster headache nod in June.  

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.